The delivery of genome editing machinery by utilizing CRISPR/Cas technology to target blood cells possesses an interesting possibility to provide cure for patients with inherited monogenic blood diseases such as sickle cell anemia and β-thalassemia. The first US FDA approved CRISPR therapeutic, Casgevy TM is an autologous gene therapy which edits BCL11A gene which helps in production of fetal hemoglobin. Eventually, this stops red blood cells (RBCs) from adopting their characteristic sickle shape. Other therapies for the treatment of sickle cell anemia and β-thalassemia include targeting the erythroid-specific enhancer region of the BCL11A gene, and HBG1/HBG2 genes and are currently undergoing clinical trials. β-thalassemia is also associated with mutations in the HBB gene, particularly a point mutation in intron 2 that alters splicing. Xu et al. used TALENs and CRISPR/Cas9 to target the aberrant intron to restore HBB gene expression in induced pluripotent stem cells (iPSCs) in vitro, creating a potential opportunity for cell therapy through haemopoietic stem cell replacement. 254